System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Alessandro M Vannucchi is an expert in Hematology at Azienda Ospedaliero-Universitaria Careggi (Italy). As of October 2026, ScienceLeadR ranks Alessandro M Vannucchi in the top 1% of experts worldwide for Hematologic Neoplasms, Blood Platelet Disorders and Embolism and Thrombosis. Alessandro M Vannucchi has authored 1,182 publications, the most recent in 2026, and is an investigator in 46 clinical trials, 8 of them ongoing. SLR score: 5,353 (community average: 125). How the SLR is computed.

LeadR Profile

Alessandro M Vannucchi Azienda Ospedaliero-Universitaria Careggi Italy
5 353 ScienceLeadR Reputation 5353

Unlock

Register Login
Network Map

Hematology

Subspecialties: Oncology - Public Health - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1988 - 2026
Source: PubMed

University of Florence

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 1182

Citations

Citations: 53 080 1st author: 96 Last author: 275 Unique author: 11

Main journals

Blood 417
Am J Hematol 84
Leukemia 79
Haematologica 58
Hemasphere 54

Best Journals

J Clin Oncol 13
N Engl J Med 9
Lancet Oncol 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
American Society of Hematology 2026 Guidelines for the Management of Myelofibrosis in Adults.
PMID 42873117 — cells, research design, hematology, anemia, signs and symptoms, therapeutics, cell transplantation, primary myelofibrosis, hematologic diseases, transplantation		Blood Adv20260
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress.
PMID 42846649 — cells, therapeutics, janus kinase inhibitors, primary myelofibrosis		Onco Targets Ther20260
Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies.
PMID 42842696 — lymphoma, neoplasms, leukemia, primary myelofibrosis		Leuk Lymphoma20260
The bidirectional relationship between JAK2V617F allele burden and inflammation in polycythaemia vera: Insights from interferon and ruxolitinib therapy.
PMID 42610025 — alleles, therapeutics		Hemasphere20260
Anemia and Patient-Reported Outcomes in Patients With Paroxysmal Nocturnal Hemoglobinuria: A Real-World Observational Study.
PMID 42583311 — quality of life, anemia, hemoglobinuria, hemolysis, patient reported outcome measures, therapeutics		EJHaem20260

Clinical Studies 46

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1

By phase:

Phase 3 23
Phase 2 11
Phase 1/Phase 2 7
Phase 1 3
N/A 1
Phase 4 1

By status:

Completed 25
Terminated 8
Active not recruiting 6
Recruiting 5
Unknown 2

By type:

Interventional 45
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 1
multicentric5to9 1
multicentricup10 44

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Phase I II with Ruxolitinib in Patients with Myelofibrosis (MF) who are Unresponsive to JAK inhibitors (HEMA MED)
2024-515252-20-00 — safety, multiple chronic conditions, janus kinase inhibitors, primary myelofibrosis		Phase 1/Phase 2Recruiting2025
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia
2023-505232-36-00 — thrombocythemia, essential, safety, thrombocytosis, therapeutics, hydroxyurea		Phase 3Active not recruiting2024
Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis
2023-504724-25-00 — thrombocythemia, essential, polycythemia vera, safety, thrombocytosis, polycythemia, random allocation, primary myelofibrosis		Phase 3Recruiting2024
A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia
2022-502514-86-00 — thrombocythemia, essential, safety, thrombocytosis, primary myelofibrosis		Phase 1Recruiting2024
A Study of Roginolisib in Combination With Ruxolitinib in Patients With Myelofibrosis (MF) Who Are Unresponsive to JAK Inhibitors
NCT06887803 — safety, multiple chronic conditions, janus kinase inhibitors, primary myelofibrosis		Phase 1/Phase 2Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS